Wednesday, February 17, 2021 Daily Archives

Takeda to expand cell therapy facility in Ireland

by

Takeda has invested €36 million in its Grange Castle facility to support the expansion of its cell therapy manufacturing facility. Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company, said its facility, located about 10km west of Dublin, will become the first commercial-scale cell therapy producton facility in Ireland, following the €36 million ($43 million) expansion.. “The expansion of the cell therapy manufacturing line in Grange Castle will help us to serve more patients worldwide,†a spokesperson for Takeda told BioProcess…

February 17, 2021

Lentiviral Vector Platform Generation: Increase Titer and Yield with Greater Predictability

by

This webcast features: Xin Xin, Group Leader, Small-Scale Upstream Process Development, and Senthil Kumar Kuppuswamy, Associate Principal Scientist, Downstream Process Development, WuXi Advanced Therapies The field of cell and gene therapies has expanded rapidly in the past several years. Lentiviral vectors have been in great demand as gene carriers in this field, especially for ex vivo gene therapies. However, large-scale lentiviral vector production still remains a significant challenge. WuXi Advanced Therapies has worked with Lentivirus since 2015 and it launched…

February 17, 2021

Affinity resins: Avitide gears up to support COVID-19 vaccine makers

by

Avitide says a specific SARS-CoV-2 virus spike protein affinity resin greatly helps the current COVID-19 efforts and could greatly accelerate the speed of response in future pandemics. Bioprocess service and consumable firms are looking to support the next wave of COVID-19 vaccines as they progress through the clinic. Last week, we reported that Repligen and Navigo launched an affinity resin specifically for the purification of COVID-19 vaccines. But they are not alone, and New Hampshire-based firm Avitide recently finalized its…

February 17, 2021